Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Annandale, VA
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Annandale, VA
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Richmond, VA
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Status: Enrolling
Updated:  12/31/1969
mi
from
Vancouver,
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Status: Enrolling
Updated: 12/31/1969
mi
from
Vancouver,
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
Miller Children's Hosp. Long Beach CA NICHD CRS
mi
from
Long Beach, CA
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
Miller Children's Hosp. Long Beach CA NICHD CRS
mi
from
Long Beach, CA
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
David Geffen School of Medicine at UCLA NICHD CRS
mi
from
Los Angeles, CA
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
David Geffen School of Medicine at UCLA NICHD CRS
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
Univ. of California San Francisco NICHD CRS
mi
from
San Francisco, CA
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
Univ. of California San Francisco NICHD CRS
mi
from
San Francisco, CA
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
Univ. of Florida Jacksonville NICHD CRS
mi
from
Jacksonville, FL
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
Univ. of Florida Jacksonville NICHD CRS
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Univ. Baltimore NICHD CRS
mi
from
Baltimore, MD
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Univ. Baltimore NICHD CRS
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
Boston Medical Center Ped. HIV Program NICHD CRS
mi
from
Boston, MA
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
Boston Medical Center Ped. HIV Program NICHD CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
St. Jude Children's Research Hospital CRS
mi
from
Memphis, TN
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Research Hospital CRS
mi
from
Memphis, TN
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Research Institute CRS
mi
from
Seattle, WA
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Research Institute CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
Usc La Nichd Crs
mi
from
Los Angeles, CA
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
Usc La Nichd Crs
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program
mi
from
La Jolla, CA
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program
mi
from
La Jolla, CA
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
Bronx-Lebanon Hospital Center NICHD CRS
mi
from
Bronx, NY
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
Bronx-Lebanon Hospital Center NICHD CRS
mi
from
Bronx, NY
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
Jacobi Med. Ctr. Bronx NICHD CRS
mi
from
Bronx, NY
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
Jacobi Med. Ctr. Bronx NICHD CRS
mi
from
Bronx, NY
Click here to add this to my saved trials
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated:  12/31/1969
Hospital Nossa Senhora da Conceicao NICHD CRS
mi
from
Porto Alegre,
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Raltegravir Pharmacokinetics and Safety in Neonates
Status: Enrolling
Updated: 12/31/1969
Hospital Nossa Senhora da Conceicao NICHD CRS
mi
from
Porto Alegre,
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Birmingham, AL
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Irvine, CA
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Irvine, CA
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
San Diego, CA
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Centennial, CO
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Centennial, CO
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Site
mi
from
Omaha, NE
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Toledo, OH
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Toledo, OH
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Frisco, TX
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Frisco, TX
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from
Edmonton,
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from
Edmonton,
Click here to add this to my saved trials
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Status: Enrolling
Updated:  12/31/1969
The Johns Hopkins HIV Care Program
mi
from
Baltimore, MD
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Status: Enrolling
Updated: 12/31/1969
The Johns Hopkins HIV Care Program
mi
from
Baltimore, MD
Click here to add this to my saved trials
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Status: Enrolling
Updated:  12/31/1969
UNC Infectious Diseases Clinic
mi
from
Chapel Hill, NC
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Status: Enrolling
Updated: 12/31/1969
UNC Infectious Diseases Clinic
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
mi
from
Seattle, WA
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Spectrum Medical Group
mi
from
Phoenix, AZ
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Spectrum Medical Group
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
AHF Research Center
mi
from
Beverly Hills, CA
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
AHF Research Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Peter J. Ruane, MD, Inc.
mi
from
Los Angeles, CA
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Peter J. Ruane, MD, Inc.
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Anthony Mills MD Inc
mi
from
Los Angeles, CA
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Anthony Mills MD Inc
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Barry M. Rodwick MD
mi
from
Clearwater, FL
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Barry M. Rodwick MD
mi
from
Clearwater, FL
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Gary J. Richmond, M.D., P.A.
mi
from
Fort Lauderdale, FL
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Gary J. Richmond, M.D., P.A.
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Midway Immunology and Research Center
mi
from
Fort Pierce, FL
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Midway Immunology and Research Center
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
AIDS Health Foundation/WPA
mi
from
Miami Beach, FL
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
AIDS Health Foundation/WPA
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
AIDS Research and Treatment Center of the Treasure Coast
mi
from
Vero Beach, FL
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
AIDS Research and Treatment Center of the Treasure Coast
mi
from
Vero Beach, FL
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Triple O Research Institute, P.A.
mi
from
West Palm Beach, FL
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Triple O Research Institute, P.A.
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Be Well Medical Center
mi
from
Berkley, MI
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Be Well Medical Center
mi
from
Berkley, MI
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
KC Care Clinic
mi
from
Kansas City, MO
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
KC Care Clinic
mi
from
Kansas City, MO
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Southwest CARE Center
mi
from
Santa Fe, NM
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Southwest CARE Center
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Central Texas Clinical Research
mi
from
Austin, TX
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Central Texas Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
St. Hope Foundation
mi
from
Bellaire, TX
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
St. Hope Foundation
mi
from
Bellaire, TX
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
North Texas Infectious Diseases Consultants, PA
mi
from
Dallas, TX
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
North Texas Infectious Diseases Consultants, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Gordon E. Crofoot MD PA
mi
from
Houston, TX
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Gordon E. Crofoot MD PA
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Peter Shalit, M.D.
mi
from
Seattle, WA
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Peter Shalit, M.D.
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated:  12/31/1969
Therapeutic Concepts, P.A.
mi
from
Houston, TX
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Status: Enrolling
Updated: 12/31/1969
Therapeutic Concepts, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials